Trade

with

Merrimack Pharmaceuticals Inc
(NASDAQ: MACK)
AdChoices
8.68
+0.24
+2.84%
After Hours :
8.80
+0.12
+1.38%

Open

8.47

Previous Close

8.44

Volume (Avg)

1.81M (1.88M)

Day's Range

8.34-8.80

52Wk Range

2.05-8.99

Market Cap.

907.82M

Dividend Rate ( Yield )

-

Beta

1.23

Shares Outstanding

104.59M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 47.79M

    • Net Income

    • -130.93M

    • Market Cap.

    • 907.82M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -213.20

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.23

    • Forward P/E

    • -8.65

    • Price/Sales

    • 16.03

    • Price/Book Value

    • -11.78

    • Price/Cash flow

    • -7.60

      • EBITDA

      • -117.16M

      • Return on Capital %

      • -99.85

      • Return on Equity %

      • -

      • Return on Assets %

      • -99.85

      • Book Value/Share

      • -0.74

      • Shares Outstanding

      • 104.59M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 14.33

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -1.00

        • Cashflow Estimate

        • -0.79

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 50.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -164.98

            • 82.75

            • Pre-Tax Margin

            • -212.78

            • 39.38

            • Net Profit Margin

            • -213.20

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -479.90

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -676.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -644.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 1.14

              • 2.92

              • Quick Ratio

              • 1.09

              • 2.35

              • Interest Coverage

              • -5.75

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.74

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.32

                • 238.10

                • P/E Ratio 5-Year High

                • -9.63

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.78

                • 124.82

                • Price/Sales Ratio

                • 15.60

                • 8.94

                • Price/Book Value

                • -11.44

                • 8.12

                • Price/Cash Flow Ratio

                • -7.60

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -99.85

                    (-79.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.47

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -120.54M
                  Operating Margin
                  -252.25
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.60
                  Ownership

                  Institutional Ownership

                  53.53%

                  Top 10 Institutions

                  38.71%

                  Mutual Fund Ownership

                  35.62%

                  Float

                  78.20%

                  5% / Insider Ownership

                  6.95%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    9,571,609

                  • 1.33

                  • 9.15

                  • Prudential Jennison Health Sciences

                  •  

                    3,018,329

                  • -20.54

                  • 2.89

                  • SPDR® S&P Biotech ETF

                  •  

                    2,351,071

                  • 0.60

                  • 2.16

                  • Fidelity® Series Growth Company Fund

                  •  

                    2,048,366

                  • 1.48

                  • 1.96

                  • Vanguard Small Cap Index

                  •  

                    1,635,528

                  • 0.75

                  • 1.56

                  • Fidelity® Blue Chip Growth Fund

                  •  

                    1,594,658

                  • 0.00

                  • 1.52

                  • iShares Russell 2000 (AU)

                  •  

                    1,544,683

                  • -0.22

                  • 1.42

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,519,091

                  • 0.00

                  • 1.45

                  • iShares Nasdaq Biotechnology

                  •  

                    1,398,093

                  • 3.08

                  • 1.29

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    1,104,962

                  • -0.95

                  • 1.06

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    15,447,572

                  • +0.15%

                  • 14.78

                  • Vanguard Group, Inc.

                  •  

                    5,396,583

                  • +2.39%

                  • 5.16

                  • Jennison Associates LLC

                  •  

                    4,837,582

                  • -17.15%

                  • 4.63

                  • BlackRock Fund Advisors

                  •  

                    4,203,723

                  • +14.89%

                  • 4.02

                  • State Street Corp

                  •  

                    3,399,276

                  • -26.77%

                  • 3.25

                  • Deutsche Bank AG

                  •  

                    2,325,201

                  • +1,633.47%

                  • 2.22

                  • Millennium Management LLC

                  •  

                    2,055,592

                  • +567.65%

                  • 1.97

                  • Northern Trust Investments, N.A.

                  •  

                    1,133,939

                  • -9.97%

                  • 1.08

                  • Putnam Investment Management,LLC

                  •  

                    867,651

                  • -14.98%

                  • 0.83

                  • UBS Global Asset Management Zurich

                  •  

                    804,997

                  • 0.00%

                  • 0.77

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  Merrimack Pharmaceuticals Inc was incorporated in the Commonwealth of Massachusetts in 1993 and reincorporated under the laws of the State of Delaware in October 2010. The Company is a biopharmaceutical company engaged in discovering...more, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer. Its core approach to systems biology is to apply multidisciplinary and multi technology capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks, that allow to engineer treatments that are directed at the mechanisms of disease. The Company currently has six targeted therapeutic oncology candidates in clinical development, are either monoclonal antibodies or ...moremonoclonal antibody-derived molecules that are designed to block oncogenic signaling pathways, such as MM-121, MM-111, MM-151 and MM-141, or nanotherapeutics, such as MM-398 and MM-302, that are designed to preferentially deliver cytotoxic therapies to the tumor tissue. MM-398 is a novel, stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors. Its Phase 3 clinical trial of MM-398 is focused on pancreatic cancer, and used in a number of other solid tumor indications, including colorectal cancer, lung cancer, breast cancer, glioma and pediatric solid tumors. Its MM-121 is a fully human monoclonal antibody that targets the ErbB3 cell surface receptor. MM-121 is designed to inhibit cancer growth directly, restore a tumor’s sensitivity to drugs to which it has become resistant, and delay the development of resistance by a tumor to other agents. Its MM-111 is a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 (HER2) cell surface receptor. MM-111 is designed to anchor to both receptors, ErbB2 (HER2) and HER3, on the cell surface and block heregulin’s ability to transmit tumor growth signals, thus inhibiting the tumor cell’s ability to thrive. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. It is designed to target and bind to cancer cells that overexpress ErbB2 (HER2) and thereby release doxorubicin at the site of the tumor, while minimizing uptake into normal cells, including those of the heart. MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of EGFR (ErbB1). MM-151 is in its Phase 1 clinical trial for patients with refractory solid tumors. Its MM-141 is a fully human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor, or IGF-1R, and ErbB3 cell surface receptors. It is designed MM-141 to suppress the PI3K/AKT/mTOR signaling pathway by reducing the levels of IGF-1R and ErbB3 receptor complexes that trigger the pathway. The Company faces competition from many different sources, including pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. The Company’s operations are subject to FDA regulates drugs and biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHSA, and implementing regulations.lessless

                  Key People

                  Robert J. Mulroy

                  CEO/Director/President

                  Mr. Gary L. Crocker

                  Chairman of the Board/Director

                  Mr. William A. Sullivan

                  CFO/Chief Accounting Officer/Treasurer

                  Mr. Jeffrey A. Munsie

                  General Counsel/Vice President

                  Dr. Michael E. Porter

                  Director

                  • Merrimack Pharmaceuticals Inc

                  • One Kendall Square

                  • Cambridge, MA 02139

                  • USA.Map

                  • Phone: +1 617 441-1000

                  • Fax: +1 617 491-1386

                  • merrimackpharma.com

                  Incorporated

                  1993

                  Employees

                  254

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: